GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Immage Biotherapeutics IMMG · USD

N/A · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2016

Net income

−$216,476

FY2014FY2016

Free cash flow

−$215,821

FY2014FY2016

Shareholders' equity

$187,288

FY2014FY2016

Income statement

Fiscal years

FY2016FY2015FY2014
Research and development$62,221$62,221$62,221
Operating income−$216,476−$58,766−$18,555
Net income−$216,476−$58,766−$18,555
Diluted earnings per share-0.00-0.00—

Balance sheet

At each fiscal year end

FY2016FY2015FY2014
Total assets$243,104$80,166$2,342
Total liabilities$55,816$51,402$23,957
Shareholders' equity$187,288$28,764−$21,615
Shares outstanding145m102m562m

Cash flow

Fiscal years

FY2016FY2015FY2014
Cash from operations−$215,821−$57,117−$17,614
Capital spending—−$44,787−$44,787
Free cash flow−$215,821−$101,904−$62,401

Latest quarters

By quarter end

Feb 2017Nov 2016Aug 2016May 2016Feb 2016Nov 2015Jun 2015Dec 2014
Operating income−$44,093−$1.7m−$61,996−$50,859−$69,600−$30,000−$20,000−$10,000
Net income−$44,093−$1.7m−$61,996−$50,859−$69,600−$30,000−$20,000−$10,000
Diluted earnings per share-0.00-0.01-0.00-0.00-0.00———
Total assets$90,812$168,892$243,104$305,131$369,700$430,000$70,000—
Cash and short-term investments————$327,800$380,000$70,000—
Debt————$52,800$430,000$50,000$20,000
Shareholders' equity$22,343$66,436$187,288$249,284$300,100−$10,000$20,000−$30,000

Growth per year

Compound annual rate

3 years5 years10 years
Operating income162.2%——
Net income162.2%——

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%0%0%0%6300%0%900%80%137%-25%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 273-for-1 split · 13 Feb 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.